Literature DB >> 35840362

TRPC channels as emerging targets for seizure disorders.

Ying Yu1, Wei Li1, Jianxiong Jiang2.   

Abstract

Epilepsy is characterized by seizures of diverse types that affect about 1-2% of the population worldwide. Current antiseizure medications are unsatisfactory, as they merely provide symptomatic relief, are ineffective in about one-third of patients, and cause unbearable adverse effects. Transient receptor potential canonical (TRPC) channels are a group of nonselective cation channels involved in many physiological functions. In this review, we provide an overview of recent preclinical studies using both genetic and pharmacological strategies that reveal these receptor-operated calcium-permeable channels may also play fundamental roles in many aspects of epileptic seizures. We also propose that TRPC channels represent appealing targets for epilepsy treatment, with a goal of helping to advance the discovery and development of new antiseizure and/or antiepileptogenic therapies.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antiseizure drugs; cation channels; epilepsy; epileptogenesis; status epilepticus; transient receptor potential channels

Mesh:

Substances:

Year:  2022        PMID: 35840362      PMCID: PMC9378536          DOI: 10.1016/j.tips.2022.06.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   17.638


  88 in total

1.  Interaction between TRPC1/TRPC4 assembly and STIM1 contributes to store-operated Ca2+ entry in mesangial cells.

Authors:  Sherry Sours-Brothers; Min Ding; Sarabeth Graham; Rong Ma
Journal:  Exp Biol Med (Maywood)       Date:  2009-03-23

Review 2.  Mechanisms of action of currently used antiseizure drugs.

Authors:  Graeme J Sills; Michael A Rogawski
Journal:  Neuropharmacology       Date:  2020-01-14       Impact factor: 5.250

3.  Contribution of TRPC Channels in Neuronal Excitotoxicity Associated With Neurodegenerative Disease and Ischemic Stroke.

Authors:  Jaepyo Jeon; Fan Bu; Guanghua Sun; Jin-Bin Tian; Shun-Ming Ting; Jun Li; Jaroslaw Aronowski; Lutz Birnbaumer; Marc Freichel; Michael X Zhu
Journal:  Front Cell Dev Biol       Date:  2021-01-08

Review 4.  Unifying mechanism behind the onset of acquired epilepsy.

Authors:  Yuri Zilberter; Irina Popova; Misha Zilberter
Journal:  Trends Pharmacol Sci       Date:  2021-12-06       Impact factor: 17.638

5.  TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation.

Authors:  Michelle D Amaral; Lucas Pozzo-Miller
Journal:  J Neurosci       Date:  2007-05-09       Impact factor: 6.167

Review 6.  Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside.

Authors:  Avijit Dey; Xu Kang; Jiange Qiu; Yifeng Du; Jianxiong Jiang
Journal:  Trends Pharmacol Sci       Date:  2016-04-06       Impact factor: 14.819

7.  The reverse roles of transient receptor potential canonical channel-3 and -6 in neuronal death following pilocarpine-induced status epilepticus.

Authors:  Duk-Soo Kim; Hea Jin Ryu; Ji-Eun Kim; Tae-Cheon Kang
Journal:  Cell Mol Neurobiol       Date:  2012-08-28       Impact factor: 5.046

8.  Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics.

Authors:  Ying Yu; Lexiao Li; Davis T Nguyen; Suni M Mustafa; Bob M Moore; Jianxiong Jiang
Journal:  Mol Neurobiol       Date:  2020-05-06       Impact factor: 5.590

9.  Canonical Transient Receptor Potential Channel 3 Contributes to Febrile Seizure Inducing Neuronal Cell Death and Neuroinflammation.

Authors:  Dan Sun; Hui Ma; Jiehui Ma; Jing Wang; Xiaolong Deng; Chunhui Hu; Xianbo Deng
Journal:  Cell Mol Neurobiol       Date:  2018-05-10       Impact factor: 5.046

10.  Structural basis for human TRPC5 channel inhibition by two distinct inhibitors.

Authors:  Kangcheng Song; Miao Wei; Wenjun Guo; Li Quan; Yunlu Kang; Jing-Xiang Wu; Lei Chen
Journal:  Elife       Date:  2021-03-08       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.